Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Related Keywords

,Precision Medicine ,Biomarker Testing ,Nsclc ,Non Small Cell Lung Cancer ,Lung Cancer ,Lung Cancer Treatment ,Perioperative Therapy ,Adjuvant Therapy ,Pdl1 ,Egfr Mutations ,Liquid Biopsy ,Tissue Utilization ,Comprehensive Biomarker Testing ,Actionable Mutations ,Kras G12c ,Ther2 ,Egfr Exon 20 ,Treatment Decision Making ,